Stockscreener 앱 받기
1.33
1.48%
-0.02
시간 외 거래:
1.33
전일 마감가:
$1.35
열려 있는:
$1.34
하루 거래량:
348.33K
Relative Volume:
0.78
시가총액:
$131.78M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-0.4508
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
-15.82%
1개월 성능:
-24.43%
6개월 성능:
-56.25%
1년 성능:
-69.14%
1일 변동 폭
$1.30
$1.37
1주일 범위
$1.28
$1.58
52주 변동 폭
$1.28
$5.38
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.33 | 131.78M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results - MarketBeat
ADC Therapeutics Strengthens Team with Major Equity Incentive Package - Stock Titan
ADC Therapeutics (NYSE:ADCT) Price Target Cut to $7.00 by Analysts at Guggenheim - MarketBeat
HC Wainwright Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire
ADC Therapeutics (NYSE:ADCT) Given “Buy” Rating at HC Wainwright - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim - Defense World
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... By GuruFocus - Investing.com Canada
Guggenheim cuts ADC Therapeutics target to $7, keeps Buy rating By Investing.com - Investing.com UK
Bank of New York Mellon Corp Buys 9,750 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ADC Therapeutics Q4 2024 beats EPS, misses revenue - Investing.com Australia
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates - MSN
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - StreetInsider.com
ADC Therapeutics targets $600M–$1B in peak ZYNLONTA revenue amid expansion into DLBCL market - MSN
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics Q4 Net Income USD -30.727 Million - MarketScreener
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Finan - GuruFocus
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue By Investing.com - Investing.com South Africa
ADC Therapeutics reports Q4 results, beats on EPS but misses revenue - Investing.com
ADC THERAPEUTICS SA -REDH Earnings Results: $ADCT Reports Quarterly Earnings - Nasdaq
A Preview Of ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation a - GuruFocus
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 – Company Announcement - Financial Times
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Bought by Platinum Investment Management Ltd. - MarketBeat
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 - BioSpace
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financ - GuruFocus
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA® - Business Wire
ADC Therapeutics Sets Date for Crucial Year-End 2024 Financial Update - Stock Titan
Antibody Drug Conjugates Market to Witness Massive Growth - openPR
WuXi XDC and AbTis collaborate for antibody-drug conjugates - Pharmaceutical Technology
ADC THERAPEUTICS SA -REDH Earnings Preview: Recent $ADCT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Cantor Fitzgerald Reiterates "Overweight" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying? - Simply Wall St
Cantor Fitzgerald Reiterates “Overweight” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (ADCT) Projected to Post Earnings on Wednesday - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - MSN
ADC Therapeutics (ADCT) to Release Earnings on Wednesday - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Stephens Analyst Says - MarketBeat
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - Armenian Reporter
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 at Stephens - Defense World
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):